CTMX Q3 2020 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+66.1% YoY

Gross Profit

$18M100.0% margin

Operating Income

-$15M-83.7% margin

Net Income

-$15M-82.7% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$375M

Total Liabilities

$327M

Stockholders' Equity

$48M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$11M	+66.1%
Gross Profit	$18M	$11M	+66.1%
Operating Income	-$15M	-$26M	+42.1%
Net Income	-$15M	-$24M	+37.9%